You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Details for New Drug Application (NDA): 206099

✉ Email this page to a colleague

« Back to Dashboard

NDA 206099 describes ONZETRA XSAIL, which is a drug marketed by Currax and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug. Additional details are available on the ONZETRA XSAIL profile page.

The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for 206099

Tradename:	ONZETRA XSAIL
Applicant:	Currax
Ingredient:	sumatriptan succinate
Patents:	16
Formulation / Manufacturing:	see details

Pharmacology for NDA: 206099

Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Suppliers and Packaging for NDA: 206099

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099	NDA	Currax Pharmaceuticals LLC	42847-311	42847-311-08	8 POUCH in 1 CARTON (42847-311-08) / 2 CAPSULE in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;NASAL			Strength	EQ 11MG BASE
Approval Date:	Jan 27, 2016	TE:		RLD:	Yes
Patent:	⤷ Try a Trial	Patent Expiration:	Oct 20, 2034	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Try a Trial	Patent Expiration:	Jul 30, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
Patent:	⤷ Try a Trial	Patent Expiration:	Jul 30, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

Expired US Patents for NDA 206099

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016	⤷ Try a Trial	⤷ Try a Trial
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016	⤷ Try a Trial	⤷ Try a Trial
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016	⤷ Try a Trial	⤷ Try a Trial
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.